Close
Nordic 9Nordic 9

Dawn Biopharma (investor - Private Equity)

United Kingdom
See something wrong or missing? Let us know
Offices:London

Dawn Biopharma is a platform controlled by the KKR Healthcare Strategic Growth Fund II

Average round investment:75.75M USD
Average number per year:3.0
Distribution: 2024 (5)2023 (1)
Portfolio companies: Denmark Antag TherapeuticsDenmark AdcendoBelgium Agomab See the entire list
Mostly invests in: Denmark Denmark (3) Health services (6)
See the entire list

Showing 3 of 6 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Dawn Biopharma mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Dawn Biopharma

Name Criteria
France Lauxera Capital Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United States Omega Funds
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Israel Pontifax Venture Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium, Netherlands, Denmark
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
United States Bristol-Myers Squibb
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States Perceptive Advisors
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
United States Menlo Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Denmark
  • Average number of deals per year: 3.2
  • Active last 12 months: Yes
United Kingdom HSBC
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium, Netherlands, Denmark
  • Average number of deals per year: 3.4
  • Active last 12 months: Yes
United States New Enterprise Associates
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands, Denmark
  • Average number of deals per year: 3.4
  • Active last 12 months: Yes
Netherlands Prosus Ventures
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands, Denmark
  • Average number of deals per year: 3.7
  • Active last 12 months: Yes
France Sanofi Ventures
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium, Denmark
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Top